logo-loader

Arix Bioscience says portfolio company Autolus to start study on leukaemia lead candidate

Published: 13:58 16 Apr 2020 BST

Arix Bioscience PLC - Arix Bioscience’s portfolio company Autolus to start study on leukemia lead candidate

Arix Bioscience PLC (LON:ARIX) announced that its portfolio company Autolus Therapeutics has received the green light for AUTO1, its lead candidate for the treatment of lymphoblastic leukaemia. 

The approval by the US Food and Drug Administration allows the first study on AUTO1 to begin.

READ: Arix Bioscience shuffles board, names Naseem Amin as executive chairman with immediate effect

Arix, an investor in breakthrough biotech companies, said the clinical study will suffer “minimal” impact from the coronavirus outbreak.

It said Autolus also continues to manufacture from its operations at the UK Cell and Gene Therapy Catapult, including supply to the US of clinical products for a study on the treatment of Diffuse Large B-cell Lymphoma.

Shares rose 2% to 83.88p on Friday afternoon.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

2 hours, 55 minutes ago